Skyrizi Alternatives Compared
| Skyrizi (risankizumab) | Apremilast | Tildrakizumab |
|
|---|
| Skyrizi (risankizumab) | Apremilast | Tildrakizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Prescription only
Apremilast is a PDE4 inhibitor that may be used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It has been associated with severe diarrhea, nausea, a... View more |
Prescription only
Prescribed for Plaque Psoriasis, Psoriasis. Tildrakizumab may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||
| More about Skyrizi (risankizumab) | More about Apremilast | More about Tildrakizumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Skyrizi has an average rating of 8.1 out of 10 from a total of 51 ratings on Drugs.com. 77% of reviewers reported a positive effect, while 15% reported a negative effect. |
Apremilast has an average rating of 5.2 out of 10 from a total of 467 ratings on Drugs.com. 36% of reviewers reported a positive effect, while 40% reported a negative effect. |
Tildrakizumab has an average rating of 5.8 out of 10 from a total of 8 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 38% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
View all Skyrizi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
N/A |
||||||||
| Brand Names | ||||||||||
|
N/A |
Otezla | Ilumya | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
672 hours |
9 hours |
552 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 176 drugs are known to interact with Skyrizi:
|
A total of 102 drugs are known to interact with Apremilast:
|
A total of 175 drugs are known to interact with Tildrakizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
March 21, 2014 |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.